Inflammatory gut bacteria that carry proteins structurally similar to myelin may trigger the development and progression of ...

Explore the significant impact of obesity on multiple sclerosis (MS) progression, including increased symptoms, disability, and comorbidities. Learn how to manage weight effectively with professional ...

MS research suggests the disease may be divided into two biological subtypes that differ in how early and aggressively nerve ...

A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease ...

A long-term study has identified a potential biomarker that could help detect which patients are progressing toward more severe forms of multiple sclerosis.

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

Disability progression independent of relapse activity (PIRA) -- sometimes referred to as silent progression -- is a key integrating concept in the contemporary view of multiple sclerosis (MS). "The ...

MS is currently treated with 'disease-modifying' medicines (e.g. interferon beta, glatiramer acetate, natalizumab, fingolimod, alemtuzumab, teriflunomide, and dimethyl fumarate). These medicines can ...

The progression of relapsing-onset multiple sclerosis (MS) and its associated disability may be slowing, results from a large population-based study suggest. In an evaluation of more than 7000 ...

In contrast to traditional measures, such as an increase or worsening of lesions or overall brain atrophy, to signal progression of multiple sclerosis (MS), investigators are proposing atrophied ...

Less than two weeks after rejecting Sanofi’s investigational multiple sclerosis drug, the FDA has publicly shared the ...